Best Liquid Biopsy Cancer Screening Companies

QIAGEN is a leading provider of Sample to Insight solutions in the molecular diagnostics and life sciences research sectors. The company offers technologies for isolating and processing DNA, RNA, and proteins, as well as assay development, bioinformatics software, and automation solutions to facilitate seamless and cost-effective workflows. QIAGEN primarily serves the healthcare and life sciences industries, including academia, pharmaceutical R&D, and industrial applications such as forensics. It was founded in 1984 and is based in Hilden, Germany.

Freenome serves as a biotechnology company focused on early cancer detection through advanced diagnostic tools. The company develops blood tests that identify early signs of cancer by analyzing biomarkers from tumor and non-tumor sources using a multiomics platform. These tests are designed to be non-invasive and accessible, aiming to detect various types of cancer at its most treatable stages. It was founded in 2014 and is based in South San Francisco, California.

Veracyte operates as a molecular diagnostics company. It focuses on discovering, developing, and commercializing molecular diagnostic solutions that enable physicians to make informed treatment decisions at an early stage in patients' treatment. It was founded in 2008 and is based in South San Francisco, California.

Guardant Health is a precision medicine company with a focus on oncology, providing advanced blood and tissue tests to inform treatment decisions for cancer patients. The company offers FDA-approved blood tests for colorectal cancer screening and a suite of products designed to support personalized treatment plans based on biomarker analysis and circulating tumor DNA. Guardant Health's solutions are utilized by healthcare providers, biopharma companies, and researchers seeking to improve clinical outcomes through data-driven insights. It was founded in 2012 and is based in Redwood City, California.

Exact Sciences focuses on the eradication of cancer through the development of diagnostic tests. It operates within the healthcare and biotechnology. It offers a range of tests aimed at preventing cancer, detecting it at an early stage, and guiding its successful treatment. These tests are primarily used in the healthcare industry for cancer diagnosis and treatment. It was founded in 1995 and is based in Madison, Wisconsin.

BillionToOne is a diagnostics company specializing in molecular diagnostics within the healthcare sector. The company offers proprietary molecular counting technology that enables accurate detection and quantification of disease-related deoxyribonucleic acid at the single base-pair level, primarily for prenatal screening and oncology testing. BillionToOne's technology serves the healthcare industry, with a focus on improving prenatal care and cancer treatment through diagnostic tests. It was founded in 2016 and is based in Menlo Park, California.

Delfi Diagnostics is a company focused on early cancer detection, operating in the healthcare and biotechnology sectors. The company's main service involves the use of novel machine-learning algorithms to analyze fragments of cell-free deoxyribonucleic acid (DNA), which allows for the accurate detection of cancer from a single blood sample. It primarily serves the healthcare industry. It was founded in 2019 and is based in Palo Alto, California.

GRAIL is a healthcare company focused on the early detection of cancer and precision oncology. The company main offerings include the Galleri test, a multi-cancer early detection test that screens for various cancers using blood samples by analyzing DNA methylation patterns with machine learning algorithms. GRAIL was formerly known as PSC15. It was founded in 2016 and is based in Menlo Park, California.

Harbinger Health is a company focused on transforming cancer care, operating within the healthcare and technology sectors. The company's main service involves the development of screening technologies that utilize artificial intelligence and insights into the biology of cancer's origin to detect cancer at its earliest stages. The company was founded in 2018 and is based in Cambridge, Massachusetts.

InterVenn is a life sciences company focused on clinical glycoproteomics and artificial intelligence within the biotechnology sector. The company offers a proprietary AI-driven platform, GlycoVision™, which enhances the speed, scope, and scale of glycoproteomics for biomarker discovery, disease detection and progression, therapeutic response, and monitoring. InterVenn primarily serves the healthcare and medical research industries with its advanced diagnostic and potentially therapeutic applications. Intervenn was formerly known as GlycoProX Biosciences. It was founded in 2017 and is based in South San Francisco, California.

Natera operates as a clinical genetic testing company. It offers a range of tests to identify diseases such as breast cancer, bladder cancer, lung cancer, gynecologic cancer, and more. The company was formerly known as Gene Security Network. The company was founded in 2004 and is based in Austin, Texas.

NeoGenomics Laboratories is a company focused on cancer diagnostics within the healthcare sector. The company offers a range of diagnostic services including cancer cytogenetics, hematologic and solid tumor FISH testing, flow cytometry, and molecular oncology tests. These services are primarily aimed at the healthcare industry, including hospital and private pathology laboratories, office-based oncologists, and academic institutions. It was founded in 2001 and is based in Fort Myers, Florida.

Personal Genome Diagnostics (PGDx) develops tests for cancer at the genomic level, which incorporate sequencing algorithms to find alterations in genomes associated with cancer. The company is developing tests of both tissue samples and blood, the latter of which is known as "liquid biopsy." It is based in Baltimore, Maryland. On December 23rd, 2021, Personal Genome Diagnostics was acquired by LabCorp at a valuation between $450M and $575M.

Singlera Genomics specializes in the development of liquid biopsy technologies for early cancer detection within the biotechnology sector. The company offers analysis reagents and software designed to determine methylation haplotypes in cell-free DNA, with assays capable of detecting cancer significantly earlier than traditional methods. Singlera's products provide cancer diagnostics through non-invasive testing and advanced bioinformatics. It was founded in 2014 and is based in Yangzhou, China.

Universal DX specializes in the development of blood-based diagnostic tests for early cancer detection within the healthcare sector. Its offerings include liquid biopsy tests that utilize a combination of multi-omics, computational biology, and machine learning to detect cancers, such as colorectal cancer, through a blood test. Universal DX's products are designed to identify cancer at its earliest stages, aiming to make the disease preventable and curable. The company was founded in 2012 and is based in Seville, Spain.